A maternal ultrasound at approximately 38 weeks gestation shows mild fetal cardiomegaly with no other significant findings. What is the recommended next step in management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Fetal Echocardiography is the Next Step

For a fetus at 38 weeks with isolated mild cardiomegaly on routine ultrasound, the next step is to perform a specialized fetal echocardiography to evaluate cardiac structure and function in detail. 1

Rationale for Fetal Echocardiography

The ACR Appropriateness Criteria clearly state that when major anomalies (including cardiomegaly) are found on second and third trimester screening, US echocardiography is usually appropriate as the next imaging study 1. This specialized examination goes beyond routine obstetric ultrasound to assess:

  • Detailed cardiac structure to rule out structural heart defects
  • Cardiac function and valve competency
  • Chamber size ratios and proportions
  • Flow patterns across valves and great vessels

Important Context: Late Gestation Physiology

A critical caveat: Some cardiac findings that appear abnormal may actually represent normal physiologic changes in late pregnancy. After 34 weeks gestation, the following are frequently seen in normal fetuses 2:

  • Tricuspid-to-mitral valve disproportion (increases with gestational age)
  • Right-to-left atrium size disproportion
  • Mild tricuspid regurgitation (present in 80% after 34 weeks)
  • Aneurysms of septum primum (80% after 34 weeks)

However, true cardiomegaly requires formal evaluation to distinguish physiologic changes from pathology.

Differential Diagnosis to Consider

The fetal echocardiography should specifically evaluate for:

Cardiac Causes (49.5% of cardiomegaly cases) 3:

  • Structural cardiac defects
  • Cardiomyopathies (dilated, hypertrophic)
  • Endocardial fibroelastosis
  • Arrhythmias

Anemic Causes (43% of cases) 3:

  • Look for associated findings: ascites, pericardial effusion, hydrops
  • These are more prevalent with anemia than cardiac abnormalities
  • Consider hemoglobinopathies, red cell alloimmunization

Secondary Causes:

  • High-output cardiac failure from arteriovenous malformations (e.g., vein of Galen malformation) 4
  • Maternal diabetes
  • Fetal infections (CMV, toxoplasmosis) 5

Additional Workup to Pursue Concurrently

While arranging fetal echocardiography:

  1. Detailed anatomy scan if not already performed - look for:

    • Ventriculomegaly
    • Fetal growth restriction
    • Pericardial effusion, ascites, hydrops
    • Placentomegaly
    • Other organ abnormalities 3, 5
  2. Maternal infectious disease screening:

    • CMV serology and amniotic fluid PCR if indicated
    • Toxoplasmosis screening
    • Parvovirus B19 if anemia suspected 5
  3. Genetic counseling and testing:

    • Chromosomal abnormalities are associated with higher mortality 3
    • Consider amniocentesis for microarray if not already done
    • Family history of cardiomyopathy 6, 7
  4. Maternal diabetes screening if not current

Prognostic Considerations

The prognosis depends heavily on the underlying cause 3:

  • Overall perinatal mortality with fetal cardiomegaly is approximately 70%
  • Cardiothoracic ratio ≥0.58 is the best predictor of perinatal mortality
  • Earlier gestational age at diagnosis, skin edema, and chromosomal abnormalities predict worse outcomes
  • Secondary causes (when treatable) have better outcomes than primary cardiac defects

Timing and Urgency

At 38 weeks, this evaluation is urgent but not emergent. The fetal echocardiography should be performed within days, not weeks, as:

  • Delivery may occur spontaneously at any time
  • Progressive cardiomegaly or development of hydrops would change management
  • Neonatal team needs to be prepared for potential resuscitation and immediate postnatal care

Delivery Planning

Based on echocardiography findings:

  • Delivery should occur at a tertiary center with pediatric cardiology and neonatal intensive care
  • Mode of delivery depends on obstetric indications unless severe cardiac compromise is present
  • Neonatal team should be present at delivery for immediate evaluation

Do not delay the echocardiography - normal cardiac findings at midtrimester do not exclude cardiomyopathy developing later in pregnancy 6.

Related Questions

In a patient with positive cytomegalovirus immunoglobulin G (CMV IgG), negative cytomegalovirus immunoglobulin M (CMV IgM), and hepatosplenomegaly on computed tomography (CT) scan, what is the clinical significance and what further evaluation and management are recommended?
In a pregnant patient whose fetus has growth restriction and positive cytomegalovirus (CMV) serology, what is the recommended next step to confirm fetal infection and guide management?
Can fetal lateral ventricles appear larger on a third‑trimester ultrasound than on earlier second‑trimester scans despite previously normal measurements?
In a fetal ultrasound, does a lateral ventricle measuring 8.9 mm, larger than the opposite ventricle, represent a concerning finding?
How should a pregnancy with fetal lateral ventriculomegaly be managed, and what folic acid supplementation regimen is recommended?
A female patient on 10 mg daily atomoxetine (Strattera) shows significant improvement in mood, ADHD, orthostatic hypotension, and OCD symptoms, with mild gastrointestinal discomfort and a delayed menstrual period; she also sleeps well even with afternoon dosing. How should the medication be managed regarding continuation, dose escalation, pregnancy testing, and monitoring for side effects?
What do the PORTEC (Post‑Operative Radiation Therapy in Endometrial Carcinoma) trials recommend for adjuvant treatment of endometrial cancer based on risk categories?
How should dalfampridine (4‑aminopyridine) be initiated, dosed, and monitored for episodic ataxia type 2, and what dose adjustments are required in renal impairment?
Do any autoimmune conditions present with features that resemble the hypermobility type of Ehlers‑Danlos syndrome?
What is the significance of a serum testosterone level of 1000 ng/dL and how should it be evaluated and managed?
Can metformin be used to treat elevated triglycerides?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.